patients [8-11]. On the contrary, Höbarth et al. [12] pointed out that the prevalence of TM in patients who underwent US owing to a variety of scrotal symptoms was 0.6%. However, this incidence has increased in the past few years owing to technological advances and raising awareness about the condition [11]. In the same vein, Pedersen et al. [13] found recently that the prevalence of TM in patients who had an US investigation of the scrotum owing to testicular/scrotal symptoms was 12.8%. Moreover, Fedder [7] demonstrated that the prevalence rate of testicular hyperechoic foci (sonographic TML= testicular microlithiasis, FSH= follicle stimulating hormone, LH= luetinizing hormone) in nonvasectomized azoospermic males is 13.4%.